ArticlePulmonary circulation2025
Incremental Burden of Pulmonary Hypertension Among Patients With Interstitial Lung Disease in the Real-World Setting.
Article in Pulmonary circulation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Incremental Burden of Pulmonary Hypertension Among Patients With Interstitial Lung Disease in the Real-World Setting.Pulmonary circulation · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary hypertension (PH) is a common complication in interstitial lung disease (ILD), but the additional burden it imposes on patients and healthcare systems is not well characterized. This retrospective analysis of claims data from the US Merative MarketScan database assessed hospitalization rates and costs over 2 years in patients with connective tissue disease-related ILD (CTD-ILD) and non-CTD-ILD with or without PH (between January 2017 and December 2019). Index was the date of first ILD claim; baseline was the 12-month preindex period. In total, 16,129 patients with non-CTD-ILD (1502 [9%] with PH) and 4545 patients with CTD-ILD (663 [15%] with PH) were identified. A higher proportion of patients with non-CTD-ILD with PH, compared with patients without PH, had all-cause and heart failure (HF)-related hospitalizations during baseline (all-cause, 37.0% vs. 22.3%; HF-related, 14.2% vs. 3.1%), 0-12 months (62.4% vs. 43.0%; 29.0% vs. 7.0%), and 13-24 months (44.7% vs. 18.3%; 21.5% vs. 3.2%) follow-up (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.